Comprehensive Stock Comparison
Compare Corcept Therapeutics Incorporated (CORT) vs BioMarin Pharmaceutical Inc. (BMRN) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth | BMRN | 12.9% revenue growth vs CORT's 12.8% |
| Value | BMRN | Lower P/E (15.4x vs 97.6x) |
| Quality / Margins | CORT | 13.0% net margin vs BMRN's 10.8% |
| Stability / Safety | BMRN | Beta 0.74 vs CORT's 1.12 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | BMRN | -13.3% vs CORT's -41.1% |
| Efficiency (ROA) | CORT | 11.8% ROA vs BMRN's 4.6%, ROIC 6.2% vs 7.4% |
Who Each Stock Is For
Income & stability
Growth exposure
Long-term compounding (10Y)
Sleep-well-at-night portfolio
Defensive / Recession hedge
Business Model
What each company does and how it makes money
Corcept Therapeutics is a pharmaceutical company focused on developing and commercializing drugs for severe metabolic, oncologic, and neuropsychiatric disorders caused by cortisol excess. It generates revenue primarily from sales of its flagship drug Korlym for Cushing's syndrome, with future growth expected from its pipeline of selective cortisol modulators targeting additional indications. The company's competitive advantage lies in its deep expertise in cortisol modulation and intellectual property around novel glucocorticoid receptor antagonists.
BioMarin Pharmaceutical is a biotechnology company focused on developing and commercializing therapies for rare genetic diseases. It generates revenue primarily from sales of its orphan drug portfolio — including Voxzogo, Vimizim, and Palynziq — with additional income from licensing and royalties. The company's moat lies in its deep expertise in rare disease biology and its established commercial infrastructure for ultra-orphan drugs, which creates high barriers to entry.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
BMRN leads in 2 of 6 categories (Valuation Metrics, Risk & Volatility). CORT leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Financial Metrics (TTM)
BMRN is the larger business by revenue, generating $3.2B annually — 4.2x CORT's $761M. Profitability is closely matched — net margins range from 13.0% (CORT) to 10.8% (BMRN). On growth, BMRN holds the edge at +17.0% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | CORTCorcept Therapeut… | BMRNBioMarin Pharmace… |
|---|---|---|
| RevenueTrailing 12 months | $761M | $3.2B |
| EBITDAEarnings before interest/tax | $47M | $613M |
| Net IncomeAfter-tax profit | $99M | $349M |
| Free Cash FlowCash after capex | $142M | $725M |
| Gross MarginGross profit ÷ Revenue | +98.3% | +77.1% |
| Operating MarginEBIT ÷ Revenue | +5.9% | +16.6% |
| Net MarginNet income ÷ Revenue | +13.0% | +10.8% |
| FCF MarginFCF ÷ Revenue | +18.6% | +22.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | +11.1% | +17.0% |
| EPS Growth (YoY)Latest quarter vs prior year | -23.1% | -134.4% |
Valuation Metrics
At 34.3x trailing earnings, BMRN trades at a 21% valuation discount to CORT's 43.5x P/E. On an enterprise value basis, BMRN's 18.2x EV/EBITDA is more attractive than CORT's 78.6x.
| Metric | CORTCorcept Therapeut… | BMRNBioMarin Pharmace… |
|---|---|---|
| Market CapShares × price | $3.8B | $11.9B |
| Enterprise ValueMkt cap + debt − cash | $3.7B | $11.1B |
| Trailing P/EPrice ÷ TTM EPS | 43.54x | 34.29x |
| Forward P/EPrice ÷ next-FY EPS est. | 97.65x | 15.45x |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | 78.58x | 18.18x |
| Price / SalesMarket cap ÷ Revenue | 4.97x | 3.68x |
| Price / BookPrice ÷ Book value/share | 6.61x | 2.00x |
| Price / FCFMarket cap ÷ FCF | 26.68x | 16.36x |
Profitability & Efficiency
CORT delivers a 15.3% return on equity — every $100 of shareholder capital generates $15 in annual profit, vs $6 for BMRN. CORT carries lower financial leverage with a 0.01x debt-to-equity ratio, signaling a more conservative balance sheet compared to BMRN's 0.10x.
| Metric | CORTCorcept Therapeut… | BMRNBioMarin Pharmace… |
|---|---|---|
| ROE (TTM)Return on equity | +15.3% | +5.7% |
| ROA (TTM)Return on assets | +11.8% | +4.6% |
| ROICReturn on invested capital | +6.2% | +7.4% |
| ROCEReturn on capital employed | +6.5% | +7.8% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 5 |
| Debt / EquityFinancial leverage | 0.01x | 0.10x |
| Net DebtTotal debt minus cash | -$114M | -$715M |
| Cash & Equiv.Liquid assets | $120M | $1.3B |
| Total DebtShort + long-term debt | $6M | $597M |
| Interest CoverageEBIT ÷ Interest expense | — | 48.95x |
Total Returns (with DRIP)
A $10,000 investment in CORT five years ago would be worth $14,022 today (with dividends reinvested), compared to $7,797 for BMRN. Over the past 12 months, BMRN leads with a -13.3% total return vs CORT's -41.1%. The 3-year compound annual growth rate (CAGR) favors CORT at 19.7% vs BMRN's -14.7% — a key indicator of consistent wealth creation.
| Metric | CORTCorcept Therapeut… | BMRNBioMarin Pharmace… |
|---|---|---|
| YTD ReturnYear-to-date | -6.5% | +3.8% |
| 1-Year ReturnPast 12 months | -41.1% | -13.3% |
| 3-Year ReturnCumulative with dividends | +71.4% | -38.0% |
| 5-Year ReturnCumulative with dividends | +40.2% | -22.0% |
| 10-Year ReturnCumulative with dividends | +834.6% | -24.6% |
| CAGR (3Y)Annualised 3-year return | +19.7% | -14.7% |
Risk & Volatility
BMRN is the less volatile stock with a 0.74 beta — it tends to amplify market swings less than CORT's 1.12 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. BMRN currently trades 84.0% from its 52-week high vs CORT's 30.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | CORTCorcept Therapeut… | BMRNBioMarin Pharmace… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.12x | 0.74x |
| 52-Week HighHighest price in past year | $117.33 | $73.51 |
| 52-Week LowLowest price in past year | $28.66 | $50.76 |
| % of 52W HighCurrent price vs 52-week peak | +30.4% | +84.0% |
| RSI (14)Momentum oscillator 0–100 | 36.5 | 56.6 |
| Avg Volume (50D)Average daily shares traded | 2.3M | 1.9M |
Analyst Outlook
Wall Street rates CORT as "Buy" and BMRN as "Buy". Consensus price targets imply 91.6% upside for CORT (target: $68) vs 32.8% for BMRN (target: $82).
| Metric | CORTCorcept Therapeut… | BMRNBioMarin Pharmace… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $68.40 | $82.00 |
| # AnalystsCovering analysts | 24 | 40 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | +6.5% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Feb 26 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 100 | 307.94 | +207.9% |
| BioMarin Pharmaceut… (BMRN) | 100 | 61.39 | -38.6% |
Corcept Therapeutic… (CORT) returned +40% over 5 years vs BioMarin Pharmaceut… (BMRN)'s -22%. A $10,000 investment in CORT 5 years ago would be worth $14,022 today (including dividends reinvested).
Chart 2Revenue Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | $81M | $761M | +836.3% |
| BioMarin Pharmaceut… (BMRN) | $1.1B | $0.00 | -100.0% |
Corcept Therapeutics Incorporated's revenue grew from $81M (2016) to $761M (2025) — a 28.2% CAGR. BioMarin Pharmaceutical Inc.'s revenue grew from $1.1B (2016) to $0M (2025) — a -100.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 10.0% | 13.1% | +30.8% |
| BioMarin Pharmaceut… (BMRN) | -56.4% | 15.0% | +126.5% |
Corcept Therapeutics Incorporated's net margin went from 10% (2016) to 13% (2025).
Chart 4P/E Ratio History — 9 Years
| Stock | 2017 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 17.4 | 42.4 | +143.7% |
| BioMarin Pharmaceut… (BMRN) | 19.4 | 424.5 | +2088.1% |
Corcept Therapeutics Incorporated has traded in a 16x–42x P/E range over 9 years; current trailing P/E is ~44x. BioMarin Pharmaceutical Inc. has traded in a 19x–425x P/E range over 5 years; current trailing P/E is ~34x.
Chart 5EPS Growth — 10 Years
| Stock | 2016 | 2025 | Change |
|---|---|---|---|
| Corcept Therapeutic… (CORT) | 0.07 | 0.82 | +1071.4% |
| BioMarin Pharmaceut… (BMRN) | -3.79 | 0.14 | +103.7% |
Corcept Therapeutics Incorporated's EPS grew from $0.07 (2016) to $0.82 (2025) — a 31% CAGR. BioMarin Pharmaceutical Inc.'s EPS grew from $-3.79 (2016) to $0.14 (2025).
Chart 6Free Cash Flow — 5 Years
Corcept Therapeutics Incorporated generated $142M FCF in 2025 (-15% vs 2021). BioMarin Pharmaceutical Inc. generated $725M FCF in 2025 (+291% vs 2021).
CORT vs BMRN: Frequently Asked Questions
9 questions · data-driven answers · updated daily
01Is CORT or BMRN a better buy right now?
BioMarin Pharmaceutical Inc. (BMRN) offers the better valuation at 34.3x trailing P/E (15.4x forward), making it the more compelling value choice. Analysts rate Corcept Therapeutics Incorporated (CORT) a "Buy" — based on 24 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — CORT or BMRN?
On trailing P/E, BioMarin Pharmaceutical Inc. (BMRN) is the cheapest at 34.3x versus Corcept Therapeutics Incorporated at 43.5x. On forward P/E, BioMarin Pharmaceutical Inc. is actually cheaper at 15.4x.
03Which is the better long-term investment — CORT or BMRN?
Over the past 5 years, Corcept Therapeutics Incorporated (CORT) delivered a total return of +40.2%, compared to -22.0% for BioMarin Pharmaceutical Inc. (BMRN). A $10,000 investment in CORT five years ago would be worth approximately $14K today (assuming dividends reinvested). Over 10 years, the gap is even starker: CORT returned +834.6% versus BMRN's -24.6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — CORT or BMRN?
By beta (market sensitivity over 5 years), BioMarin Pharmaceutical Inc. (BMRN) is the lower-risk stock at 0.74β versus Corcept Therapeutics Incorporated's 1.12β — meaning CORT is approximately 51% more volatile than BMRN relative to the S&P 500. On balance sheet safety, Corcept Therapeutics Incorporated (CORT) carries a lower debt/equity ratio of 1% versus 10% for BioMarin Pharmaceutical Inc. — giving it more financial flexibility in a downturn.
05Which has better profit margins — CORT or BMRN?
Corcept Therapeutics Incorporated (CORT) is the more profitable company, earning 13.1% net margin versus 10.8% for BioMarin Pharmaceutical Inc. — meaning it keeps 13.1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: BMRN leads at 16.6% versus 5.9% for CORT. At the gross margin level — before operating expenses — CORT leads at 98.3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
06Is CORT or BMRN more undervalued right now?
On forward earnings alone, BioMarin Pharmaceutical Inc. (BMRN) trades at 15.4x forward P/E versus 97.6x for Corcept Therapeutics Incorporated — 82.2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CORT: 91.6% to $68.40.
07Which pays a better dividend — CORT or BMRN?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
08Is CORT or BMRN better for a retirement portfolio?
For long-horizon retirement investors, Corcept Therapeutics Incorporated (CORT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 1.12), +834.6% 10Y return). Both have compounded well over 10 years (CORT: +834.6%, BMRN: -24.6%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
09What are the main differences between CORT and BMRN?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.